OTCMKTS:RSLSD ReShape Lifesciences (RSLSD) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free RSLSD Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume6,500 shsAverage Volume1,362 shsMarket Capitalization$1.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ReShape Lifesciences alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About ReShape Lifesciences Stock (OTCMKTS:RSLSD)ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.Read More Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. RSLSD Stock News HeadlinesSeptember 21, 2023 | finanznachrichten.deReShape Lifesciences Inc: ReShape Lifesciences Signs Exclusive License Agreement With Biorad Medisys for Obalon Gastric Balloon SystemSeptember 21, 2023 | finance.yahoo.comReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon SystemJune 26, 2023 | finance.yahoo.comReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0June 14, 2023 | finance.yahoo.comReShape Lifesciences® to Participate in Investor and Industry Conferences in JuneMay 17, 2023 | insidermonkey.comReShape Lifesciences Inc. (NASDAQ:RSLS) Q1 2023 Earnings Call TranscriptApril 20, 2023 | finance.yahoo.comReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-MarketApril 12, 2023 | marketwatch.comReShape Lifesciences(R) Receives Notice of Allowance for U.S. Patent Related to its Obalon(R) Balloon SystemApril 11, 2023 | finance.yahoo.comReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon SystemMarch 31, 2023 | seekingalpha.comReShape Lifesciences postpones earnings releaseMarch 28, 2023 | msn.comEarnings Outlook For Reshape LifesciencesFebruary 8, 2023 | benzinga.comReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public OfferingFebruary 3, 2023 | msn.comWhy Is Reshape Lifesciences (RSLS) Stock Up 136% Today?November 14, 2022 | seekingalpha.comReShape Lifesciences Inc. (RSLS) Q3 2022 Earnings Call TranscriptNovember 14, 2022 | yahoo.comReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 2, 2022 | benzinga.comReShape Lifesciences to Present at the Q4 Investor SummitSeptember 24, 2022 | stockhouse.comReShape Lifesciences(TM) Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation(TM) DeviceSeptember 22, 2022 | nz.finance.yahoo.comReShape Lifesciences™ Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ DeviceSeptember 14, 2022 | nz.finance.yahoo.comReShape Lifesciences Announces Participation in the A.G.P Virtual MedTech ConferenceSeptember 9, 2022 | msn.comReshape Lifesciences's Return On Capital Employed OverviewAugust 23, 2022 | finance.yahoo.comReShape Lifesciences Appoints Seasoned Sales and Marketing Executive, Nick Ansari, as Senior Vice President of Global Commercial OperationsAugust 16, 2022 | seekingalpha.comReShape Lifesciences Inc. (RSLS) CEO Paul Hickey on Q2 2022 Results - Earnings Call TranscriptAugust 16, 2022 | finance.yahoo.comReShape Lifesciences™ Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateAugust 12, 2022 | msn.comReshape Lifesciences Earnings OutlookAugust 10, 2022 | nz.finance.yahoo.comReShape Lifesciences™ Receives FDA 510(k) Clearance for the GIBI HD™ Calibration Tubes for use in Gastric and Bariatric ProceduresJune 17, 2022 | finance.yahoo.comReShape Lifesciences Enters into Warrant Exercise Transaction for $2.5 Million in Gross ProceedsSee More Headlines Receive RSLSD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReShape Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:RSLSD CUSIPN/A CIKN/A Webwww.reshapelifesciences.com Phone949-429-6680FaxN/AEmployees43Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,150,000.00 Net Margins-668.58% Pretax MarginN/A Return on Equity-163.22% Return on Assets-52.10% Debt Debt-to-Equity Ratio0.05 Current Ratio1.17 Quick Ratio1.07 Sales & Book Value Annual Sales$610,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.08 Book Value$341.84 per share Price / BookN/AMiscellaneous Outstanding Shares354,000Free FloatN/AMarket Cap$1.90 million OptionableNot Optionable Beta2.03 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Barton P. Bandy (Age 58)Pres, CEO & Director Dr. Mark B. Knudson (Age 70)Co-Founder and Special Advisor to the CEO Dr. Katherine S. Tweden Ph.D. (Age 58)Co-Founder Mr. Thomas Stankovich (Age 58)Chief Financial Officer Mr. Vipul ShahSr. VP of Operations and R&DKey CompetitorsSintx TechnologiesNASDAQ:SINTNon-Invasive Monitoring SystemsOTCMKTS:NIMUQualigen TherapeuticsNASDAQ:QLGNIntellipharmaceutics InternationalOTCMKTS:IPCIFPaxMedicaNASDAQ:PXMDView All Competitors RSLSD Stock Analysis - Frequently Asked Questions How do I buy shares of ReShape Lifesciences? Shares of RSLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:RSLSD) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersBill Gates is all about this tiny $2 stockTimothy SykesThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReShape Lifesciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.